Windlas Biotech Ltd (WINDLAS) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company reported its 13th consecutive quarter of record revenue, demonstrating strong and consistent growth momentum.
- Performance was driven by a robust 20% YoY growth in the generic formulation CDMO vertical, which now constitutes a significant portion of the business.
- The company maintained strong capital efficiency, reflected in ROCE and ROE sustained above the 25% mark, and generated 105 crores in net operating cash flows for the full year.
- Strategic investments in new facilities are paying off, with Plant 4 and Plant 5 (injectable facility) receiving GMP certification from the Philippines, and Plant 6 on track for commercialization by H1 FY27.
- The company closed the year with a strong net liquidity position of 251 crores, positioning it for future growth and capital allocation opportunities, including a 47 crore buyback and a proposed dividend of 6.3 per share.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.